Short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting.

Short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting.